Early intravitreal bevacizumab for nonâ€ischaemic cen

Acta Ophthalmologica 87, 77-81 DOI: 10.1111/j.1755-3768.2008.01313.x

Citation Report

#	Article	IF	CITATIONS
1	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. Retina, 2009, 29, 875-912.	1.7	215
2	Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Current Opinion in Ophthalmology, 2009, 20, 511-519.	2.9	45
4	Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. , 2010, , CD007325.		24
5	Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye, 2010, 24, 810-815.	2.1	35
6	Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion. Journal of Korean Ophthalmological Society, 2010, 51, 707.	0.2	7
7	Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion. Current Vascular Pharmacology, 2010, 8, 51-58.	1.7	1
8	Results of bevacizumab as the primary treatment for retinal vein occlusions. British Journal of Ophthalmology, 2010, 94, 1052-1056.	3.9	68
9	Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion – A Matched-Pairs Analysis. Ophthalmologica, 2010, 224, 126-132.	1.9	15
11	Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions. Acta Ophthalmologica, 2010, 88, e24-5.	1.1	6
12	Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin [®]). Acta Ophthalmologica, 2010, 88, 836-841.	1.1	13
13	Intravitreal Bevacizumab for Macular Edema Due to Central Retinal Vein Occlusion: Perfused vs. Ischemic and Early vs. Late Treatment. Current Eye Research, 2011, 36, 1164-1170.	1.5	15
14	The Short-Term Efficacy of Intravitreal Ranibizumab for Macular Edema in Central Retinal Vein Occlusion. Journal of Korean Ophthalmological Society, 2011, 52, 1048.	0.2	3
15	Intravitreal Bevacizumab in Central Retinal Vein Occlusion: 18-month Results of a Prospective Clinical Trial. European Journal of Ophthalmology, 2011, 21, 789-795.	1.3	21
16	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Retina, 2011, 31, 1449-1469.	1.7	131
17	Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study. Eye, 2011, 25, 239-244.	2.1	14
18	Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Eighteen-Month Results of a Prospective Trial. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 615-621.	1.4	28
19	Retinal Vein Occlusions. Asia-Pacific Journal of Ophthalmology, 2012, 1, 355-363.	2.5	1
20	Visual Acuity Outcome and Predictive Factors after Bevacizumab for Central Retinal Vein Occlusion. European Journal of Ophthalmology, 2012, 22, 1013-1018.	1.3	30

ιτλτιώνι Ρερώ

CITATION REPORT

#	Article	IF	CITATIONS
21	Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion. Drugs, 2012, 72, 2063-2071.	10.9	4
22	Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Acta Ophthalmologica, 2012, 90, 357-361.	1.1	15
23	Combination therapy in diabetic macular oedema and retinal vein occlusion – past and present. Acta Ophthalmologica, 2012, 90, 580-589.	1.1	25
24	A clinical study to evaluate the efficacy of intravitreal Anti-VEGF therapy in treating macular edema due to retinal venous occlusions. Medical Journal Armed Forces India, 2013, 69, 260-267.	0.8	3
25	Intravitreal Triamcinolone Acetonide Compared With Bevacizumab for the Treatment of Patients With Macular Edema Secondary to Central Retinal Vein Occlusion. Postgraduate Medicine, 2013, 125, 51-58.	2.0	16
26	Meta-Analysis of the Effect of Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide in Central Retinal Vein Occlusion. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 826-831.	1.4	5
27	Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion. Indian Journal of Ophthalmology, 2014, 62, 279.	1.1	8
28	Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion. Documenta Ophthalmologica, 2014, 129, 27-38.	2.2	9
29	Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up. Seminars in Ophthalmology, 2015, 31, 1-6.	1.6	6
30	Intravitreal anti-VEGF Treatment in Central Retinal Vein Occlusion (CRVO): a Meta-Analysis of One Year Results. Klinische Monatsblatter Fur Augenheilkunde, 2017, 234, 546-550.	0.5	6
31	The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 13248.	3.3	42
32	Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. International Journal of Ophthalmology, 2011, 4, 89-94.	1.1	11